Updated:
IQVIA
IQVIA is a global healthcare analytics and clinical research firm headquartered in Danbury, CT, serving biopharma with AI-driven technology and patient...
IQVIA
IQVIA, formerly known as Quintiles and IMS Health, was formed through a 2016 merger that combined one of the world's largest CROs with the leading healthcare data provider. The firm is headquartered in Danbury, Connecticut, and operates under the legal structure of a publicly traded company (NYSE: IQV), not a family office or private investment vehicle. IQVIA's strategy is built on three pillars: clinical trial services, real-world evidence and analytics, and technology solutions. The firm runs Phase I through Phase IV clinical studies across therapeutic areas, with notable work in oncology, neurology, and rare diseases. It directly manages clinical trials for over 1,000 biopharma sponsors annually and processes data from more than 100 million de-identified patient records (per company filings, 2024). Geographic reach spans North America, Europe, Asia Pacific, and Latin America. The firm employs over 80,000 professionals globally, including scientists, data engineers, and regulatory consultants. Its technology arm, known as Q2 Solutions or IQVIA Technologies, offers cloud-based platforms like IQVIA Clinical Data Management and IQVIA Connected Intelligence. No adjacent philanthropic or operating company vehicles were identified in public sources. IQVIA's structural differentiator is its dual role as both a data platform and a service provider — it competes with CROs like Labcorp and data firms like Flatiron Health, but its model combines both. Succession follows the publicly traded corporate structure with a board of directors and CEO succession plan, reducing family-office governance risks.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Danbury
Corporate office
Danbury, CT, United States
Sector focus
Frequently asked questions
Who runs investment decisions at IQVIA?
IQVIA is a publicly traded company (NYSE: IQV) with a board of directors led by CEO Ari Bousbib, who has served since 2016. Investment decisions for capital allocation — including R&D spending, acquisitions, and clinical trial investments — are made by the executive management team under board oversight (per SEC filings, 2025).
Is IQVIA structured as a family office or a commercial enterprise?
IQVIA is a publicly traded, for-profit corporation, not a family office. It generates revenue through contracts for clinical research, data licensing, and technology subscription services. Its NYSE listing and SEC filings confirm its status as a commercial entity, not a private capital vehicle (per IQVIA 10-K, 2024).
What investment stages does IQVIA target?
IQVIA does not function as an investment firm but as a service provider. However, it does make strategic acquisitions to enhance its technology and data capabilities, typically targeting early- to growth-stage healthcare IT and analytics companies. Recent acquisitions include 2022's purchase of Healthward (per IQVIA press release, 2022).
Which sectors does IQVIA explicitly focus on?
IQVIA operates exclusively within healthcare — covering pharmaceuticals, biotechnology, medical devices, and diagnostics. It does not service other industries such as finance, energy, or consumer goods (public record).
How does IQVIA source proprietary deal flow?
IQVIA's deal flow comes from its existing biopharma client relationships and the RFP processes for clinical trials. Proprietary data from its patient record database also informs new service offerings and technology development (per company overview, 2024).
Does IQVIA maintain philanthropic structures?
IQVIA does not disclose a separate philanthropic foundation in public filings. However, it operates corporate social responsibility initiatives, including the IQVIA Foundation, which directs grants to global health programs (per IQVIA CSR report, 2024).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: